Page 2 - Fraser Wright News Today

Kriya Therapeutics is launching a new division, Kriya Ophthalmology, focused on developing gene therapies for rare and prevalent ocular diseases.

Share this article PALO ALTO, Calif., May 5, 2021 /PRNewswire/ --  Genascence Corporation, a clinical-stage biotechnology company developing life-changing gene therapy products for prevalent musculoskeletal diseases, today announced that dosing across all three cohorts has been completed in the Phase 1 clinical trial of GNSC-001 for the treatment of osteoarthritis (OA). GNSC-001 is an adeno-associated vector (AAV) carrying a coding sequence for interleukin-1 receptor antagonist (IL-1Ra), a pot...